Is longer duration of proton pump inhibitor trial better for gastroesophageal reflux disease-related non-cardiac chest pain?
Wu
Justin C Y
JC
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage*; D002637:Chest Pain / Q000188:drug therapy* / Q000209:etiology; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D036262:Empirical Research; D016145:Endoscopy, Digestive System; D050782:Esophageal pH Monitoring; D005764:Gastroesophageal Reflux / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D011237:Predictive Value of Tests; D054328:Proton Pump Inhibitors / Q000008:administration & dosage*; D064750:Rabeprazole; D012107:Research Design; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D054328:Proton Pump Inhibitors; D064750:Rabeprazole